definiens: fo r purposes of Section 6.2 shall mean an indication(s ) in an approved IND filing with the FDA for the Licensed Product or Licensed Service by Licensee or sublicensee . Once a milestone has become due based on a given achievement inside a given the same milestone shall not be due a second time if the same product achieves the same event with respect to another aspect of the same 6.7 In the event Licensee enters a Licensed Product into clinical development for a given clinical indic ation ( ) and the clinical development is stopped, then any milestone payments made for such Original Licensed Product shall be creditable against milestone payments owed for a subsequently or concurrently developed Licensed Produ ct for the same clinical indication that uses the same pathway, mechanisms and target ( ) . In the case of concurrently developed Licensed Products, the Original Licensed Product need not fail in order for the credit to apply . T he parties agree that only two Replacement Licensed Products can receive credit for the milestone payment made for an Original Licensed Product . To be eligible for such credit, Licensee must identify the Replacement Licensed Project, in writing, to The Reg ents promptly upon its substitution or concurrent development